Printed from https://ideas.repec.org/s/spr/eujhec9.html
Content
September 2007, Volume 8, Issue 3
- 267-277 Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis
by Stuart Peacock & Jeffrey Richardson - 279-285 Is there an association between economic performance and public satisfaction in health care?
by Eddy Adang & George Borm - 287-295 Why do patients bypass the nearest hospital? An empirical analysis for orthopaedic care and neurosurgery in the Netherlands
by Marco Varkevisser & Stéphanie Geest - 297-300 Economic aspects of the new Spanish laws on pharmaceutical preparations
by Fernando Antoñanzas & Juan Oliva & Mariola Pinillos & Carmelo Juàrez
June 2007, Volume 8, Issue 2
- 83-88 The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience
by László Gulácsi - 89-95 Pharmacoeconomic studies in Italy: a critical review of the literature
by D. Cornago & L. Li Bassi & P. Compadri & L. Garattini - 97-103 The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management
by Vesna Bjegovic & Zorica Terzic & Jelena Marinkovic & Nebojsa Lalic & Sandra Sipetic & Ulrich Laaser - 105-110 Patients’ willingness to pay for electronic communication with their general practitioner
by Trine Bergmo & Silje Wangberg - 111-121 Systematic review of economic evaluations and cost analyses of guideline implementation strategies
by Luke Vale & Ruth Thomas & Graeme MacLennan & Jeremy Grimshaw - 123-135 Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
by Maureen Rutten-van Mölken & Jan Oostenbrink & Marc Miravitlles & Brigitta Monz - 137-144 The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49
by Richard Norman & D. Evans & Douglas Easton & Kenneth Young - 145-151 Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system
by K. Le Lay & E. Myon & S. Hill & L. Riou-Franca & D. Scott & M. Sidhu & D. Dunlop & R. Launois - 153-160 An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany
by Sara Sheriff & K. Petry & Hans Ikenberg & Geoffrey Crouse & Peter Mazonson & Christopher Santas - 161-168 Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis
by Andrew Palmer & William Valentine & Joshua Ray & Stephane Roze & Noemi Muszbek - 169-170 Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
by Joshua Cohen - 171-171 Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen
by Livio Garattini - 173-177 Discussion point: should governments buy drug patents?
by Juan Llano
March 2007, Volume 8, Issue 1
- 1-3 Should we really worry about “launch delays” of new drugs in OECD countries?
by Livio Garattini & Simone Ghislandi - 5-15 Cost of breast cancer in Sweden in 2002
by Mathias Lidgren & Nils Wilking & Bengt Jönsson - 17-24 Better primary physician services lead to fewer hospital admissions
by Fredrik Carlsen & Jostein Grytten & Julie Kjelvik & Irene Skau - 25-30 Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy
by Peter Lindgren & Thomas Kahan & Neil Poulter & Martin Buxton & Patrick Svarvar & Björn Dahlöf & Bengt Jönsson - 31-39 Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set
by Corinne Behrend & Florian Buchner & Michael Happich & Rolf Holle & Peter Reitmeir & Jürgen Wasem - 41-50 Long-term absenteeism due to sickness in Sweden. How long does it take and what happens after?
by Daniela Andrén - 51-57 Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
by B. Brüggenjürgen & P. Lindgren & B. Ehlken & H.-J. Rupprecht & S. Willich - 59-65 A multilevel analysis on the determinants of regional health care expenditure: a note
by Guillem López-Casasnovas & Marc Saez - 67-76 Resource use and costs associated with patients treated for depression in primary care
by P. Sobocki & M. Ekman & H. Ågren & I. Krakau & B. Runeson & B. Mårtensson & B. Jönsson - 77-82 A public–private analysis of the new Dutch health insurance system
by Hans Maarse & Yvette Bartholomée
September 2007, Volume 8, Issue 1
- 1-2 Economic evaluation for pharmaceuticals in Germany
by Bengt Jönsson - 3-3 Technology assessment in the German context
by Michael Drummond - 5-31 Methods for determining cost-benefit ratios for pharmaceuticals in Germany
by J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner
December 2006, Volume 7, Issue 4
- 223-224 Time for a common standard for cost-effectiveness in Europe?
by Bengt Jönsson - 225-230 Optional deductibles in social health insurance systems
by Claudia Pütz & Christian Hagist - 231-237 A decomposition of income-related health inequality applied to EQ-5D
by Jens Gundgaard & Jørgen Lauridsen - 238-246 Cost effectiveness of preventive home visits to the elderly
by Christian Kronborg & Mikkel Vass & Jørgen Lauridsen & Kirsten Avlund - 247-254 Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction
by A. Gerber & T. Evers & H. Haverkamp & K. Lauterbach - 255-264 Cost-effectiveness of the Danish smoking cessation interventions
by Kim Olsen & Lone Bilde & Henrik Juhl & Niels Kjaer & Holger Mosbech & Torben Evald & Mette Rasmussen & Helle Hiladakis - 265-269 The demand for private health care under national health insurance
by Y. Machnes - 270-275 Economic cost associated with type II diabetes in Spanish patients
by Miguel Ballesta & Florentino Carral & Gabriel Olveira & José Girón & Manuel Aguilar - 276-284 Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany
by Alan Brennan & Roberta Ara & Raimund Sterz & Bernd Matiba & Rito Bergemann - 285-289 Tests of stationarity and cointegration of health care expenditure and gross domestic product
by Halil Kiymaz & Yasemin Akbulut & Ahmet Demir - 290-296 Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany
by W. Greiner & K. Lehmann & S. Earnshaw & C. Bug & R. Sabatowski
September 2006, Volume 7, Issue 3
- 155-157 Risk-sharing agreements for innovative drugs
by Gérard Pouvourville - 158-164 Nonmedical economic consequences attributable to visual impairment
by Antoine Lafuma & Antoine Brezin & Francis Fagnani & Viviane Mimaud & Mounir Mesbah & Gilles Berdeaux - 165-172 A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany
by Stephen Beard & Fiona Maciver & Johannes Clouth & Eckart Rüther - 173-178 Test-retest reliability of willingness to pay
by Alan Shiell & Penelope Hawe - 179-184 The costs of schizophrenia in Spain
by Juan Oliva-Moreno & Julio López-Bastida & Rubén Osuna-Guerrero & Angel Montejo-González & Beatriz Duque-González - 185-191 Health care in the CIS countries
by Anatoly Pilyavsky & Matthias Staat - 192-194 Problems and costs associated with alcohol and drug abuse in emergency medicine
by F.-X. Huber & T. Hackert & P. Meeder - 195-203 Determinants of household health expenditure on western institutional health care
by Tin Su & Subhash Pokhrel & Adjima Gbangou & Steffen Flessa - 204-211 Price regulation and generic competition in the pharmaceutical market
by Dag Dalen & Steinar Strøm & Tonje Haabeth - 212-217 Alcohol-related mortality, drinking behavior, and business cycles
by Edvard Johansson & Petri Böckerman & Ritva Prättälä & Antti Uutela - 218-220 Decision models in the evaluation of psychotropic drugs
by Corrado Barbui & Camilla Lintas
July 2006, Volume 7, Issue 2
- 5-13 Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bengt Jönsson - 14-23 Costs and quality of life of multiple sclerosis in Austria
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass - 24-33 Costs and quality of life for patients with multiple sclerosis in Belgium
by Gisela Kobelt - 34-44 Costs and quality of life of multiple sclerosis in Germany
by Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube - 45-54 Costs and quality of life of multiple sclerosis in Italy
by Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli - 55-64 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & J. Berg & P. Lindgren - 65-74 Costs and quality of life of multiple sclerosis in Spain
by Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado - 75-85 Costs and quality of life of multiple sclerosis in Sweden
by Jenny Berg & P. Lindgren & Sten Fredrikson & Gisela Kobelt - 86-95 Costs and quality of life of multiple sclerosis in Switzerland
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz - 96-104 Costs and quality of life of multiple sclerosis in the United Kingdom
by Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon
July 2006, Volume 7, Issue 02
- 5-13 Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bengt Jönsson - 14-23 Costs and quality of life of multiple sclerosis in Austria
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass - 24-33 Costs and quality of life for patients with multiple sclerosis in Belgium
by Gisela Kobelt - 34-44 Costs and quality of life of multiple sclerosis in Germany
by Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube - 45-54 Costs and quality of life of multiple sclerosis in Italy
by Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli - 55-64 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & J. Berg & P. Lindgren - 65-74 Costs and quality of life of multiple sclerosis in Spain
by Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado - 75-85 Costs and quality of life of multiple sclerosis in Sweden
by Jenny Berg & P. Lindgren & Sten Fredrikson & Gisela Kobelt - 86-95 Costs and quality of life of multiple sclerosis in Switzerland
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz - 96-104 Costs and quality of life of multiple sclerosis in the United Kingdom
by Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon
June 2006, Volume 7, Issue 2
- 89-90 Pharmaceutical policy in Italy
by Livio Garattini & Dante Cornago - 91-98 The reasons of general practitioners for promoting colorectal cancer mass screening in France
by Célia Berchi & Jean-Marc Dupuis & Guy Launoy - 99-106 Choices and utilization in dental care
by Lien Nguyen & Unto Häkkinen - 107-113 Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer
by Samuel Limat & Claire-Hélène Bracco-Nolin & Christine Legat-Fagnoni & Loic Chaigneau & Ulrich Stein & Bernard Huchet & Xavier Pivot & Marie-Christine Woronoff-Lemsi - 114-116 Health care and patients’ migration across Spanish regions
by David Cantarero - 117-122 The future of imaging techniques for cancer patients in The Netherlands
by Theo Postma & Janneke Alers & Sijmon Terpstra & Arjan Zuurbier - 123-128 Factors influencing the costs of emergency medical admissions to an Irish teaching hospital
by Edward Moloney & Kathleen Bennett & Bernard Silke - 129-136 Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers
by Hans-Georg Eichler & Sheldon Kong & Jean-Pierre Grégoire - 137-144 Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain
by Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume - 145-146 Costs of chemotherapy in the treatment of colorectal cancer
by F. Jansman & M. Postma - 147-151 A taxonomy of health utility assessment methods and the role for uncertainty analysis
by Agota Szende & Caroline Schaefer
March 2006, Volume 7, Issue 1
- 5-6 The desirability and feasibility of economic studies of drugs post-launch
by Michael Drummond & Anne Mason & Adrian Towse - 7-18 The relationship between health care expenditure and health outcomes
by John Nixon & Philippe Ulmann - 19-29 Pharmacoeconomic modelling in schizophrenia
by Karina Hansen & Christophe Lançon & Mondher Toumi - 30-36 Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients
by Monica Merito & Patrizio Pezzotti - 37-45 Fixed budgets as a cost containment measure for pharmaceuticals
by David Granlund & Niklas Rudholm & Magnus Wikström - 46-54 The Danish effect on Swedish alcohol costs
by Johan Jarl & Ulf-G. Gerdtham & Carl Lyttkens & Thor Lithman & Juan Merlo - 55-65 Prospective casemix-based funding, analysis and financial impact of cost outliers in all-patient refined diagnosis related groups in three Belgian general hospitals
by Magali Pirson & Dimitri Martins & Terri Jackson & Michèle Dramaix & Pol Leclercq - 66-71 Case-control analysis of the financial cost of medication errors in hospitalized patients
by Jaime Pinilla & Carles Murillo & Genís Carrasco & Carlos Humet - 72-78 Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care
by Steven Edwards & Helen Campbell & Jonathan Plumb - 79-83 Off-patent drugs in Italy
by Livio Garattini & Simone Ghislandi
December 2005, Volume 6, Issue 4
- 285-287 How much are health-care systems prepared to pay to produce a QALY?
by Martin Buxton - 288-297 Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris
by Helen Campbell & Sue Tait & Linda Sharples & Noreen Caine & Timothy Gray & Peter Schofield & Martin Buxton - 298-308 Does testing for prostate-specific antigen contribute to declining prostate cancer mortality?
by L. Di Matteo & R. Di Matteo - 309-313 Indirect costs of cervical and breast cancers in Spain
by Juan Oliva & Félix Lobo & Julio López-Bastida & Néboa Zozaya & Rosa Romay - 314-316 Discrete choice experiments in health economics: Distinguishing between the method and its application
by Emily Lancsar & Cam Donaldson - 317-321 Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany
by Werner Kulp & J.-M. Schulenburg & Wolfgang Greiner - 322-333 Hospital development plans
by Steffen Fleßa - 334-346 Can economic evaluations be made more transferable?
by Stephanie Boulenger & John Nixon & Michael Drummond & Philippe Ulmann & Stephen Rice & Gerard Pouvourville - 347-353 Estimating utility data from clinical indicators for patients with stable angina
by Louise Longworth & Martin Buxton & Mark Sculpher & David Smith - 354-362 The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention
by Anna Ringborg & Peter Lindgren & Bengt Jönsson
September 2005, Volume 6, Issue 3
- 191-196 Health economic evaluation of disease management programs
by Wolfgang Greiner - 197-202 The economic and quality of life impact of hypoglycemia
by Jonas Lundkvist & Christian Berne & Björn Bolinder & Linus Jönsson - 203-214 Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule
by Catherine Lejeune & Kazem Al Zahouri & Marie-Christine Woronoff-Lemsi & Patrick Arveux & Alain Bernard & Christine Binquet & Francis Guillemin - 215-222 Institutional arrangements and efficiency of health care delivery systems
by Vasanthakumar Bhat - 223-232 A cross-national perspective on cost of illness
by Johan Polder & Willem Meerding & Luc Bonneux & Paul Maas - 233-243 An empirical analysis of tobacco addiction in Italy
by Silvia Tiezzi - 244-252 Influenza treatment with neuraminidase inhibitors
by Beate Sander & Marlene Gyldmark & Frederick Hayden & James Morris & Elvira Mueller & Rito Bergemann - 253-260 Measuring health-related utility:
by Stirling Bryan & Louise Longworth - 261-266 Comparison of general practitioner records and patient self-report questionnaires for estimation of costs
by Hema Mistry & Martin Buxton & Louise Longworth & Judy Chatwin & Robert Peveler - 267-273 The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland
by Lesley Tilson & Kathleen Bennett & Michael Barry - 274-279 Reimbursement and clinical guidance for pharmaceuticals in Sweden
by Anders Anell & Ulf Persson
June 2005, Volume 6, Issue 2
- 91-93 Practice guidelines based on clinical and economic evidence
by Frans Rutten & Werner Brouwer & Louis Niessen - 94-101 Costs of hospitalization for severe acute asthma of patients not treated according to guidelines and recommendations
by Jean-Claude Sailly & Xavier Lenne & Caroline Bercez & Thérèse Lebrun & Antoine-Bernard Tonnel & Isabelle Tillie-Leblond - 102-106 Cost of home palliative care compared with conventional hospital care for patients with haematological cancers in Greece
by Sofia Tzala & Joanne Lord & Nikolaos Ziras & Panayotis Repousis & Anna Potamianou & Evangelia Tzala - 107-111 Time preference bias in time trade-off
by Marjon Pol & Larissa Roux - 112-123 Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany
by Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Wolfgang Greiner & Ulrike Ravens-Sieberer & Pamela Aidelsburger & Bärbel Kurth & Monika Bullinger & J.-Matthias Schulenburg & John Wong & Siegbert Rossol - 124-130 Validating the EQ-5D with time trade off for the German population
by W. Greiner & C. Claes & J. J. V. Busschbach & J.-M. Schulenburg - 131-135 Spatial competition for quality in the market for hospital care
by Marcello Montefiori - 136-145 Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom
by J. Guest & J. Russ & A. Lenox-Smith - 146-151 Order bias in estimates of willingness to pay for drugs to treat attention-deficit/hyperactivity disorder
by Annemieke De Ridder & Diana De Graeve - 152-158 Risk and potential risk reduction in diabetes type 2 patients in Germany
by Bertram Häussler & Ursula Berger & Oliver Mast & Wolfgang Thefeld - 159-165 Economic burden of hepatitis C in Canada and the potential impact of prevention
by Susie El Saadany & Douglas Coyle & Antonio Giulivi & Mohammad Afzal - 166-171 The direct medical cost of diabetes in Israel
by Gabriel Chodick & Anthony Heymann & Francis Wood & Ehud Kokia - 172-182 The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation
by Christophe Legendre & Stephen Beard & Anne Crochard & Yvon Lebranchu & Claire Pouteil-Noble & Anke Richter & Isabelle Durand-Zaleski - 183-187 German health care system in transition
by J.-Matthias Schulenburg
March 2005, Volume 6, Issue 1
- 2-7 Criteria for determining a basic health services package
by E. Stolk & M. Poley - 8-15 Consumer preferences in social health insurance
by Jan Kerssens & Peter Groenewegen - 16-23 Modeling the economic burden of diseases imputable to stress at work
by Sophie Béjean & Hélène Sultan-Taïeb - 30-37 The cost-effectiveness of human papillomavirus screening for cervical cancer
by Jeremy Holmes & Lindsay Hemmett & Susan Garfield - 38-44 Collecting unit cost data in multicentre studies
by Sarah Wordsworth & Anne Ludbrook & Fergus Caskey & Alison Macleod - 45-52 Bayesian regression models for cost-effectiveness analysis
by Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset - 53-64 Substance abuse treatment, what do we know?
by Matilde Machado - 65-72 A modified three-stage data envelopment analysis
by Jos Blank & Vivian Valdmanis - 73-82 A ‘new and improved’ EQ-5D valuation questionnaire?
by Nancy Devlin & Paul Hansen & Peter Herbison & Susan Macran - 83-86 On the (mis)use of cross-price effects to gauge the effectiveness of smokeless tobacco in smoking cessation
by Richard Ault & T. Beard & John Jackson & Richard Saba
November 2005, Volume 6, Issue 1
- 2-10 Defining the “Health Benefit Basket” in nine European countries
by J. Schreyögg & T. Stargardt & M. Velasco-Garrido & R. Busse - 11-17 The “Health Benefit Basket” in Denmark
by Lone Bilde & Anni Ankjaer-Jensen & Bent Danneskiold-Samsøe - 18-23 Does the English NHS have a ‘Health Benefit Basket’?
by Anne Mason - 24-29 The “Health Benefit Basket” in France
by Martine Bellanger & Veneta Cherilova & Valérie Paris - 30-36 Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany
by Reinhard Busse & Tom Stargardt & Jonas Schreyögg - 37-45 Benefits and entitlements in the Hungarian health care system
by Peter Gaal - 46-52 The “Essential Levels of Care” in Italy: when being explicit serves the devolution of powers
by Aleksandra Torbica & Giovanni Fattore - 53-57 The “Health Benefit Basket” in The Netherlands
by Elly Stolk & Frans Rutten - 58-65 Definition of the “Health Benefit Basket” in Poland
by Adam Kozierkiewicz & Wojciech Trąbka & Artur Romaszewski & Krzysztof Gajda & Dariusz Gilewski - 66-72 Spanish health benefits for services of curative care
by Ivan Planas-Miret & Ana Tur-Prats & Jaume Puig-Junoy
November 2004, Volume 5, Issue 4
- 287-289 Using diagnosis-related groups
by M. Lungen & B. Dredge & A. Rose & C. Roebuck & E. Plamper & K. Lauterbach - 290-298 Re-scaling social preference data: implications for modelling
by Irina Cleemput & Paul Kind & Katrien Kesteloot - 299-308 Willingness to pay for dental fear treatment
by Bente Halvorsen & Tiril Willumsen - 309-316 What reimbursement for coronary revascularization with drug-eluting stents?
by Rosanna Tarricone & Monia Marchetti & Mark Lamotte & Lieven Annemans & Peter Jong - 317-323 A method for cross-sector priority setting
by Tugrul Temel - 324-329 Drug price regulation under consumer moral hazard
by Stefan Felder - 330-334 Direct medical costs of monitoring and treating patients with Takayasu arteritis in Italy
by Iva Krulichova & Sara Gamba & Elena Ricci & Livio Garattini - 335-340 A note on the impact of hours worked on mortality in OECD countries
by Edvard Johansson - 341-344 The high cost of medicines in Ireland
by Lesley Tilson & Bernadette McGowan & Kathleen Bennett & Michael Barry - 345-350 Approval times and the safety of new pharmaceuticals
by Niklas Rudholm - 351-356 Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden
by Joakim Ramsberg & Stefan Odeberg & Andreas Engström & Douglas Lundin - 357-364 Data envelopment analysis based bonus payments
by Stefan Felder & Horst Schmitt - 365-367 Exponential health utility
by Lars Østerdal
September 2004, Volume 5, Issue 3
- 199-202 Discrete choice experiments in health economics
by Stirling Bryan & Paul Dolan - 203-208 Side effects of generic competition?
by Jörgen Hellström & Niklas Rudholm - 209-215 Estimating rural households’ willingness to pay for health insurance
by Ali Asgary & Ken Willis & Ali Taghvaei & Mojtaba Rafeian - 216-226 Measuring and comparing the (in)efficiency of German and Swiss hospitals
by Lukas Steinmann & Gunnar Dittrich & Alexander Karmann & Peter Zweifel - 227-235 Costs and consequences of botulinum toxin type A use
by Francis Ruiz & Julian Guest & Almut Lehmann & Alison Davie & Karen Güttler & Olaf Schlüter & Götz Dreiss - 236-242 Economics and health promotion
by Luke Connelly - 243-251 The cost structure of lung tuberculosis in Germany
by Roland Diel & Bernhard Rappenhöner & Tom Schaberg - 252-258 Financing of health care services in Hungary
by Imre Boncz & Júlia Nagy & Andor Sebestyén & László Kőrösi - 259-262 Health care provider payment mechanisms in the new EU members of Central Europe and the Baltic states
by Agota Szende & Zsolt Mogyorosy - 263-269 Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies
by Hindrik Vondeling & Peter Iversen - 270-273 Costs of treatment of colorectal cancer in different settings in Germany
by Klaus Hieke & Ulrich Kleeberg & Martina Stauch & Axel Grothey - 274-277 Out-patient drug policy by clinical assessment rather than financial constraints?
by Marja Pronk & Gouke Bonsel - 278-284 A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain
by Juan Gómez-Gerique & Roman Casciano & Lee Stern & Javier Rejas
May 2004, Volume 5, Issue 2
- 95-109 The risk-adjusted vision beyond casemix (DRG) funding in Australia
by Kathryn Antioch & Michael Walsh - 110-115 Pricing of pharmaceuticals
by Mark Nuijten & Joszef Kosa - 115-115 The risk-adjusted vision beyond casemix (DRG) funding in Australia
by Kathryn Antioch & Michael Walsh - 116-121 Genetic screening, health care and the insurance industry
by Diego Ossa & Adrian Towse - 122-128 Price-cost margin in the pharmaceutical industry
by Ismo Linnosmaa & Raine Hermans & Taru Hallinen - 129-135 Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease
by Thomas Hoffmann & Helmut Brunner - 136-142 Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients
by Janne Martikainen & Hannu Valtonen & Tuula Pirttilä - 143-149 Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine
by Francis Fagnani & Camille Fur & Isabelle Durand & Michel Gibergy - 150-165 An empirical analysis of the demand for physician services across the European Union
by Sergi Jiménez-Martín & José Labeaga & Maite Martínez-Granado - 166-174 Economic growth, longevity and the epidemiological transition
by Olivier Morand - 175-182 Dynamic competition in pharmaceuticals
by Laura Magazzini & Fabio Pammolli & Massimo Riccaboni - 183-187 The European Network of Health Economic Evaluation Databases (EURO NHEED) Project
by John Nixon & Philippe Ulmann & Julie Glanville & Stéphanie Boulenger & Michael Drummond & Gérard Pouvourville - 188-189 “Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”
by Nick Bansback & Sue Ward & Jon Karnon - 190-194 Pricing and reimbursement of drugs in Ireland
by Michael Barry & Lesley Tilson & Máirín Ryan
February 2004, Volume 5, Issue 1
- 6-14 Evaluating the effect of care programs for elderly persons with dementia on caregiver’s well-being
by Agnes Gramain & Laëtitia Malavolti - 15-21 Direct medical costs unequivocally related to diabetes in Italian specialized centers
by Livio Garattini & Francesca Chiaffarino & Dante Cornago & Carlo Coscelli & Fabio Parazzini - 22-27 Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments
by Livio Garattini & Emanuela Castelnuovo & Paolo Lanzetta & Cecilia Viscarra & Elena Ricci & Fabio Parazzini - 28-35 Priority setting for pharmaceuticals
by Anders Anell - 36-45 Economic valuation of informal care
by Bernard Berg & Werner Brouwer & Marc Koopmanschap - 45-45 An exponential representation of health state utility
by Michael Happich & Axel Muehlbacher - 46-53 The burden of varicella in Germany
by Kurt Banz & Stefan Wagenpfeil & Albrecht Neiss & Thomas Hammerschmidt & Peter Wutzler - 54-57 Do costs of varicella justify routine infant vaccination?
by M. Postma & J. Bos & R. Welte & R. Groot & W. Luytjes & H. Rümke & P. Beutels - 58-63 Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy
by Franz Hessel & Christoph Wegner & Johannes Müller & Christina Glaveris & Jürgen Wasem - 64-69 Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards
by Jörg Ruof & Jan Hülsemann & Thomas Mittendorf & Silke Handelmann & Rick Aultman & J. Schulenburg & Henning Zeidler & Sonja Merkesdal